Prescription Hearing Aids
FDA-regulated prescription hearing aids dispensed through audiologists and ENT practices, ranging from basic amplification to advanced AI-powered and rechargeable devices.
Market snapshot
These figures describe Hearing Devices & Cochlear Implants (4.8.6), the segment that Prescription Hearing Aids sits within. They are not figures for Prescription Hearing Aids on its own.
Within electromedical apparatus (NAICS 334510) and surgical appliances (339113); the Census Bureau does not split out hearing devices, so the segment is not separately sized.
Business model & economics
Revenue model
Device sales through audiology, retail, and OTC channels
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 18–28%
- Capex intensity
- High
replacement cycles and accessories
Characteristics
- Hearing aids a consolidated global oligopoly.
- OTC authorization opened a consumer channel.
- Aging-related hearing loss drives demand.
M&A deal context
Who’s acquiring
- Hearing-device strategics
- Consumer-audio & OTC entrants
- Audiology-retail consolidators
What’s driving deals
- OTC hearing-aid channel disruption.
- Aging-related hearing-loss demand.
- Consolidation of audiology distribution.
Find Prescription Hearing Aids acquisition targets
Search Acquisera’s index for companies classified under Prescription Hearing Aids (4.8.6.5) and build a targeted deal pipeline.
Search companies